Institutional members access full text with Ovid®

Share this article on:

Labeling Changes for Topiramate (Topamax) and Doripenem (Doribax)

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: July 2014 - Volume 114 - Issue 7 - p 22–23
doi: 10.1097/01.NAJ.0000451677.35953.ab
Drug Watch
  • The Food and Drug Administration (FDA) has approved the antiepileptic drug topiramate (Topamax) for a new indication, the prevention of migraines in adolescents ages 12 to 17.
  • The FDA has added a new warning to the labeling of the antibiotic doripenem (Doribax), which now warns that the drug increases the risk of death if used to treat ventilator-associated bacterial pneumonia, an off-label use.
© 2014 Lippincott Williams & Wilkins. All rights reserved.